Finnrick, an independent testing programme, publishes 16 assays for Rethel Jinan New Energy Technology: 4 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 12 did not. Most recent assay 30 Jul 2026.
Rethel Jinan New Energy Technology operates from China, listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/rethel-jinan-new-energy-technology.
Rethel Jinan New Energy Technology is listed as active.
No independent third-party assay is on file for Rethel Jinan New Energy Technology, and its storefront did not respond when we last tried to read it. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Tirzepatide | 11 | 3 passed, 8 failed |
| Retatrutide | 5 | 1 passed, 4 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
Rethel Jinan New Energy Technology is listed as active and we hold 16 Finnrick assays (4 passing, 12 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 16 assays for Rethel Jinan New Energy Technology: 4 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 12 did not. Most recent assay 30 Jul 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Revico Labs Peptides Review, Reviv Peptides Review, Rhome Research Peptides Review.